At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNCX Quince Therapeutics, Inc.
Trading 10-08 15:15:55 EDT
29.34
+2.62
+9.81%
High29.34Low26.84Vol22.54K
Open27.10D1 Closing26.72Amplitude9.36%
Mkt Cap29.84MTradable Cap19.94MTotal Shares1.02M
T/O635.68KT/O Rate3.32%Tradable Shares679.70K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quince Therapeutics Holds Special Shareholder Meeting
Reuters  ·  10-07 04:58
Quince Therapeutics Holds Special Shareholder Meeting
Quince Therapeutics Names Leone Patterson Audit, Compensation Committee Chair in Board Overhaul
Reuters  ·  10-02
Quince Therapeutics Names Leone Patterson Audit, Compensation Committee Chair in Board Overhaul
Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)
TIPRANKS  ·  09-30
Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)
Quince Therapeutics to Host Virtual KOL Event on PH-ILD, BOS Treatment Landscape and LAM-001
Reuters  ·  09-17
Quince Therapeutics to Host Virtual KOL Event on PH-ILD, BOS Treatment Landscape and LAM-001
Quince Therapeutics Flags NASDAQ Noncompliance After Stockholders’ Equity Falls to ($35.32 Million)
Reuters  ·  09-04
Quince Therapeutics Flags NASDAQ Noncompliance After Stockholders’ Equity Falls to ($35.32 Million)
Quince Therapeutics President Charles Ryan to Exit Sept. 8
Reuters  ·  08-28
Quince Therapeutics President Charles Ryan to Exit Sept. 8
Quince Therapeutics Announces Special Shareholder Meeting
Reuters  ·  08-25
Quince Therapeutics Announces Special Shareholder Meeting
Craig-Hallum bullish on Quince Therapeutics, initiates with a Buy
TIPRANKS  ·  08-20
Craig-Hallum bullish on Quince Therapeutics, initiates with a Buy
Quince Therapeutics : Leerink Partners Adjusts Target Price to $68 from $4 to Reflect 1-for-20 Reverse Stock Split
THOMSON REUTERS  ·  08-18
Quince Therapeutics : Leerink Partners Adjusts Target Price to $68 from $4 to Reflect 1-for-20 Reverse Stock Split
Quince Therapeutics Raises USD 115 Million in Private Placement of Series C Preferred Shares
Reuters  ·  08-17
Quince Therapeutics Raises USD 115 Million in Private Placement of Series C Preferred Shares
Quince Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14
Quince Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Quince Therapeutics Q2 Net Loss Widens on Acquisition Charges
Reuters  ·  08-14
Quince Therapeutics Q2 Net Loss Widens on Acquisition Charges
Press Release: Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Dow Jones  ·  08-14
Press Release: Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Quince Therapeutics, Inc. Expected to Post a Loss of $17.88 a Share - Earnings Preview
Reuters  ·  08-07
Quince Therapeutics, Inc. Expected to Post a Loss of $17.88 a Share - Earnings Preview
Quince Therapeutics - Brigette Roberts Conditionally Appointed as Chief Executive Officer - SEC Filing
THOMSON REUTERS  ·  08-01
Quince Therapeutics - Brigette Roberts Conditionally Appointed as Chief Executive Officer - SEC Filing
Quince Therapeutics Names Brigette Roberts CEO in Management Reshuffle
Reuters  ·  08-01
Quince Therapeutics Names Brigette Roberts CEO in Management Reshuffle
Quince Therapeutics Announces Special Shareholder Meeting
Reuters  ·  08-01
Quince Therapeutics Announces Special Shareholder Meeting
Quince Therapeutics - Offers 15,470,099 Shares of Common Stock for Resale - SEC Filing
THOMSON REUTERS  ·  08-01
Quince Therapeutics - Offers 15,470,099 Shares of Common Stock for Resale - SEC Filing
Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)
TIPRANKS  ·  07-31
Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)
Quince Therapeutics : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $82
THOMSON REUTERS  ·  07-29
Quince Therapeutics : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $82

Introduction

Company Name.
Quince Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Issue price:
--